Canada Markets closed

Pacific Edge Limited (PFGTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.20000.0000 (0.00%)
At close: 09:30AM EDT

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter MeintjesChief Exec. OfficerN/AN/AN/A
Mr. Grant GibsonChief Financial OfficerN/AN/AN/A
Ms. Demi StefanovaChief Operating OfficerN/AN/AN/A
Mr. Justin HarveyChief Technology OfficerN/AN/AN/A
Dr. Parry Guilford Ph.D.Chief Scientific Officer & Member of Scientific Advisory Board83.69kN/AN/A
Mr. Jack AtchasonSr. VP of Sales & Customer Service, Pacific Edge Diagnostics USA LimitedN/AN/AN/A
Mr. Andrew McIntoshChief of Information Systems & Decision SupportN/AN/AN/A
Ms. Jacqueline F. WalkerChief Exec. Officer of Pacific Edge Diagnostics USAN/AN/AN/A
Mr. Tony LoughVP of Clinical Science & Product Performance, Pacific Edge Pty LimitedN/AN/AN/A
Mr. Brent PownallVP of Commercial & FranchiseN/AN/AN/A
Amounts are as of December 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; Cxbladder Triage, a product that analyses the gene expression of urine-based biomarkers alongside information on known bladder cancer risk factors like age, gender, and smoking history to rule out patients with a low risk of having the disease; Cxbladder Detect that can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures; and Cxbladder Monitor, which is a non-invasive and easy-to-use test to rule out the return of bladder cancer. In addition, the company is developing Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limited’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.